Skip to search formSkip to main contentSkip to account menu

KW 0761

Known as: KW-0761, KW0761 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

mogamulizumab

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
A phase I and randomized phase II etctn study of KW-0761 (Mogamulizumab) and MK-3475 (Pembrolizumab) in relapsed and refractory diffuse large B-cell lymphoma.
TPS8072Background: Diffuse large B-cell lymphoma (DLBCL) escapes host immune responses via inhibition of the B2M and CD58… 
2014
2014
Phase 3 study of anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat in relapsed or refractory cutaneous T-cell lymphoma (CTCL).
TPS8623 Background: CC chemokine receptor 4 (CCR4) is selectively expressed on type 2 helper T cells and certain functional… 
2014
2014
A Phase II Open-Label, Multi-Center Study of Anti-CCR4 Monoclonal Antibody Mogamulizumab (KW-0761) in Patients with Previously Treated Peripheral T-Cell Lymphoma(PTCL)
Background CC chemokine receptor 4 (CCR4) is the receptor for macrophage-derived chemokine (MDC/CCL22) and thymus activation… 
2014
2014
Gain-of-function CCR 4 mutations in adult T cell leukemia / lymphoma
Adult T cell leukemia/lymphoma (ATLL) is one of the most aggressive forms of peripheral T cell lymphoma, with a median survival… 
2013
2013
Randomized phase II study of mogamulizumab (KW-0761) plus VCAP-AMP-VECP (mLSG15) versus mLSG15 alone for newly diagnosed aggressive adult T-cell leukemia-lymphoma (ATL).
8506 Background: Mogamulizumab (Moga), a defucosylated humanized anti-CCR4 antibody, was approved for the treatment of relapsed… 
Review
2012
Review
2012
Multicenter Phase II Study of Mogamulizumab (KW-0761), a Defucosylated Anti-CCR4 Antibody, in Patients with Relapsed Peripheral and Cutaneous T-Cell Lymphoma
Abstract 795 Background: Mogamulizumab (KW-0761) is a humanized anti-CCR4 antibody engineered to exert potent ADCC by… 
Review
2012
Review
2012
Novel and emerging drugs for rarer chronic lymphoid leukaemias.
Rarer chronic lymphoid leukaemias represent a challenge to the clinicians due to the limited information on their pathogenesis… 
2011
2011
Effects of Anti-CCR4 Antibody (KW-0761) on Regulatory T Cells and Natural Killer Cells in Patients with Cutaneous T-Cell Lymphoma
Abstract 444 The CC chemokine receptor 4 (CCR4) is expressed on malignant T-cells in cutaneous T-cell lymphoma (CTCL) and also on… 
2008
2008
Phase I Study of KW-0761, a Defucosylated Anti-CCR4 Antibody, in Relapsed Patients (Pts) with Adult T-Cell Leukemia-Lymphoma (ATL) or Peripheral T-Cell Lymphoma (PTCL): Updated Results.
Background: KW-0761 produced by POTELLIGENT ® technology is a defucosylated humanized IgG1 monoclonal antibody against CC… 
2007
2007
Phase I Study of KW-0761, a Humanized Anti-CCR4 Antibody, in Patients (Pts) with Relapsed or Refractory Adult T-Cell Leukemia-Lymphoma (ATLL) and Peripheral T-Cell Lymphoma (PTCL): Preliminary…
Introduction: KW-0761 is a defucosylated humanized IgG1 monoclonal antibody against CC chemokine receptor 4 (CCR4). Previous… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)